Nerandomilast slows progression of pulmonary fibrosis

IF 32.7 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2025-07-08 DOI:10.1038/s41584-025-01285-y

Maria Papatriantafyllou

引用次数: 0

Abstract

The anti-fibrotic and anti-inflammatory agent nerandomilast has shown promise for the treatment of both idiopathic and progressive pulmonary fibrosis in phase III trials.

查看原文本刊更多论文

奈兰多司特减缓肺纤维化的进展

抗纤维化和抗炎药nerandomilast在III期试验中显示出治疗特发性和进行性肺纤维化的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.